好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

KMT2B early childhood onset dystonia presenting as failure to thrive
Child Neurology and Developmental Neurology
P4 - Poster Session 4 (5:30 PM-6:30 PM)
7-034
We report a 15 year old girl presenting with failure to thrive secondary to novel likely pathogenic variant in the KMT2B gene. Our case increases awareness of this potentially treatable condition and highlights an unusual presentation.
Mutations in KMT2B gene cause childhood, lower limb onset generalized dystonia with prominent cranial, cervical, and laryngeal involvement. Other manifestations may include mild intellectual disability, behavioral abnormalities, dysmorphism, and non-neurologic features. Many patients with KMT2B dystonia may have sustained clinical improvement with deep brain stimulation.
Case Report, Trio whole genome sequencing

Our patient presented to the emergency department with multiple complaints having not seen a physician for 2 years due to financial constraints.  History was notable for gait abnormality onset age 3, speech dysfluency from age 9, and dysphagia from age 13. Family history was notable for mother with right arm pain and handwriting difficulty onset age 29 and two maternal cousins (age 4 and 5) with failure to thrive and non-specific developmental motor concerns. On exam, weight was below 1%ile for age. She had left foot inversion contracture, generalized dystonia with marked oro-lingual involvement, and severe dysfluency. Imaging identified a left 5th metatarsal fracture. Medical neglect was considered as an etiology for failure to thrive. Fluoroscopic dysphagia study revealed aspiration and g-tube was placed. MRI brain showed moderate symmetric hypointensity along the bilateral globi pallidi. Trio whole genome sequencing revealed a novel missense variant in the KMT2B gene in mother and daughter. Subsequent examination of mother showed right arm and leg dystonia that had been previously unrecognized.

 

Patients presenting with failure to thrive with abnormal neurologic signs should undergo genetic testing to allow for precise diagnosis of rare genetic conditions that may be potentially treatable.

Authors/Disclosures
Andrew Ng, MD (CHLA Neurology)
PRESENTER
No disclosure on file
Serena Galosi, MD (Sapienza University of Rome/ UCSD and Rady Children'S Hispital) No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Jennifer R. Friedman, MD (UCSD/Rady Children'S Hospital) An immediate family member of Dr. Friedman has received personal compensation in the range of $0-$499 for serving as a Consultant for Sinopia Biosciences. An immediate family member of Dr. Friedman has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Pet Dx. Dr. Friedman has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MedLink Neurology. Dr. Friedman has stock in Friedman Bioventure .